Related Experiment Video
Updated: Jan 11, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Disseminated Intravascular Coagulation Following ¹⁷⁷Lu-Dotatate Therapy in a Patient With Metastatic Midgut
1Haematology, Launceston General Hospital, Launceston, AUS.
Abstract:
Peptide receptor radionuclide therapy (PRRT) is an expanding field with ¹⁷⁷Lu-Dotatate emerging as a treatment for midgut neuroendocrine tumours. Haematological side effects are infrequent, and the treatment is generally well tolerated. We present the case of a 70-year-old male patient who developed spontaneous bruising five weeks after his first dose of ¹⁷⁷Lu-Dotatate, with investigations consistent with disseminated intravascular coagulation (DIC). After initially requiring substantial transfusion support, the patient's DIC resolved with the commencement of corticosteroid therapy. This case suggests that DIC may be a rare subacute complication of ¹⁷⁷Lu-Dotatate, and that corticosteroids could be an effective component of management in such instances.

![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)